Mevalonate kinase deficiency associated with ataxia and retinitis pigmentosa in two brothers with MVK gene mutations

2017 ◽  
Vol 38 (4) ◽  
pp. 340-344 ◽  
Author(s):  
Ulrich Kellner ◽  
Heidi Stöhr ◽  
Silke Weinitz ◽  
Ghazaleh Farmand ◽  
Bernhard H. F. Weber
Ophthalmology ◽  
2013 ◽  
Vol 120 (12) ◽  
pp. 2697-2705 ◽  
Author(s):  
Anna M. Siemiatkowska ◽  
L. Ingeborgh van den Born ◽  
P. Martin van Hagen ◽  
Monique Stoffels ◽  
Kornelia Neveling ◽  
...  

2005 ◽  
Vol 28 (6) ◽  
pp. 1143-1145 ◽  
Author(s):  
B. Balgobind ◽  
D. Wittebol-Post ◽  
J. Frenkel

2020 ◽  
Author(s):  
Jack A. Bibby ◽  
Harriet A. Purvis ◽  
Thomas Hayday ◽  
Anita Chandra ◽  
Klaus Okkenhaug ◽  
...  

SummaryRegulatory B cells restrict immune and inflammatory responses across a number of contexts. This capacity is mediated primarily through the production of IL-10. Here we demonstrate that the induction of a regulatory program in human B cells is dependent on a metabolic priming event driven by cholesterol metabolism. Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate (GGPP) was required to specifically drive IL-10 production, and to attenuate Th1 responses. Furthermore, GGPP-dependent protein modifications controlled signaling through PI3Kδ-AKT-GSK3, which in turn promoted BLIMP1-dependent IL-10 production. Inherited gene mutations in cholesterol metabolism result in a severe autoinflammatory syndrome, termed mevalonate kinase deficiency (MKD). Consistent with our findings, B cells from MKD patients induced poor IL-10 responses and were functionally impaired. Moreover, metabolic supplementation with GGPP was able to reverse this defect. Collectively, our data define cholesterol metabolism as an integral metabolic pathway for the optimal functioning of human IL-10 producing regulatory B cells.Graphical abstractMKD = Mevalonate kinase deficiency


2011 ◽  
Vol 21 (6) ◽  
pp. 641-645 ◽  
Author(s):  
Masahiro Tahara ◽  
Hidemasa Sakai ◽  
Ryuta Nishikomori ◽  
Takahiro Yasumi ◽  
Toshio Heike ◽  
...  

Author(s):  
Puneet Kumar Choudhary ◽  
Vivek Parihar ◽  
Jagatshreya Satapathy ◽  
Narendra Kumar Bagri

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Harry O. Orlans ◽  
Michelle E. McClements ◽  
Alun R. Barnard ◽  
Cristina Martinez-Fernandez de la Camara ◽  
Robert E. MacLaren

AbstractRhodopsin (RHO) gene mutations are a common cause of autosomal dominant retinitis pigmentosa (ADRP). The need to suppress toxic protein expression together with mutational heterogeneity pose challenges for treatment development. Mirtrons are atypical RNA interference effectors that are spliced from transcripts as short introns. Here, we develop a novel mirtron-based knockdown/replacement gene therapy for the mutation-independent treatment of RHO-related ADRP, and demonstrate efficacy in a relevant mammalian model. Splicing and potency of rhodopsin-targeting candidate mirtrons are initially determined, and a mirtron-resistant codon-modified version of the rhodopsin coding sequence is validated in vitro. These elements are then combined within a single adeno-associated virus (AAV) and delivered subretinally in a RhoP23H knock-in mouse model of ADRP. This results in significant mouse-to-human rhodopsin RNA replacement and is associated with a slowing of retinal degeneration. This provides proof of principle that synthetic mirtrons delivered by AAV are capable of reducing disease severity in vivo.


2006 ◽  
Vol 27 (8) ◽  
pp. 796-802 ◽  
Author(s):  
Saskia H.L. Mandey ◽  
Marit S. Schneiders ◽  
Janet Koster ◽  
Hans R. Waterham

1997 ◽  
Vol 20 (3) ◽  
pp. 391-394 ◽  
Author(s):  
K. M. Gibson ◽  
G. F. Hoffmann ◽  
L. Sweetman ◽  
B. Buckingham

Sign in / Sign up

Export Citation Format

Share Document